September: New Imported Drug Approvals by the NMPA - August 2024
□ Aclidinium Bromide Powder for Inhalation (Brand; N/A) – marketed by Covis Pharma Europe B.V.
□ Atracurium Besilate Injection (Brand; N/A) – marketed by Joint Stock Company “Kalceks”
□ Benralizumab Injection (Brand; Fasenra) – marketed by AstraZeneca AB
□ Enfortumab vedotin for Injection (Brand; PADCEV) – marketed by Astellas Pharma Europe B.V.
□ Estradiol and Dydrogesterone Tablets (Brand; N/A) – marketed by Abbott B.V.
□ Trastuzumab Deruxtecan for Injection (Brand; Enhertu) – new indication in HER2+ locally advanced or metastatic gastric or GEJ - marketed by Daiichi Sankyo Europe GmbH
